Page last updated: 2024-11-06

sisomicin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sisomicin is an aminoglycoside antibiotic derived from Micromonospora inyoensis. It is a broad-spectrum antibiotic with activity against a wide range of gram-negative bacteria, including Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae. It is often used to treat serious infections, particularly those caused by multidrug-resistant bacteria. Sisomicin is typically administered intravenously or intramuscularly. Its mechanism of action involves binding to the 16S ribosomal RNA of bacterial ribosomes, leading to misreading of the genetic code and inhibition of protein synthesis. Sisomicin has been extensively studied for its therapeutic potential and its use in combination with other antibiotics to overcome resistance. The compound's potential for adverse effects such as nephrotoxicity and ototoxicity necessitates careful monitoring during treatment. Ongoing research is focused on exploring novel ways to administer sisomicin to improve its efficacy and minimize adverse events. '

Sisomicin: Antibiotic produced by Micromonospora inyoensis. It is closely related to gentamicin C1A, one of the components of the gentamicin complex (GENTAMICINS). [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID36119
CHEMBL ID221886
CHEBI ID9169
SCHEMBL ID49395
MeSH IDM0019903

Synonyms (58)

Synonym
siso
D02544
sisomicin (usan/inn)
SIS ,
(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yloxy]-2-hydroxycyclohexyl 3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranoside
CHEBI:9169 ,
sissomicin
o-2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-glycero-hex-4-enopyranosyl-(1-4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1-6))-2-deoxy-d-streptamine
32385-11-8
dehydrogentamicin cla
antibiotic 6640
rickamicin
sisomicin
C00494
(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[[(2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy]-2-hydroxy-cyclohexoxy]-5-methyl-4-(methylamino)tetrahydropyran-3,5-diol
sch-13475
d-streptamine, o-3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1-6)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-glycero-hex-4-enopyranosyl-(1-4))-2-deoxy-
antibiotic 66-40
sisomycin
brn 1357913
(2s-cis)-4-o-(3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl)-2-deoxy-6-o-(3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl)-d-streptamine
sch 13475
sisomicinum [inn-latin]
o-2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-glycero-hex-4-enopyranosyl-(1-4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1-6)-2-deoxy-d-streptamine
sisomicina [inn-spanish]
sisomicine [inn-french]
o-3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1-4)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-glycero-hex-4-enopyranosyl-(1-6))-2-deoxy-l-streptamine
einecs 251-018-2
(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[[(2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
sch13475
(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[[3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
sisomicina
sisomicine
sisomicinum
unii-x55xsl74yq
x55xsl74yq ,
sisomicin [usan:inn:ban]
CHEMBL221886
(1s,2s,3r,4s,6r)-4,6-diamino-3-{[(2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy}-2-hydroxycyclohexyl 3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranoside
AKOS015895179
SCHEMBL49395
sisomicin [inn]
netilmicin sulfate impurity a [ep impurity]
gentamicin sulfate impurity a [ep impurity]
sisomicin [usan]
(2s-cis)-4-o-(3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl)-2-deoxy-6-o-(3-deoxy-4-c-methyl-3-(methylamino)-.beta.-l-arabinopyranosyl)-d-streptamine
2-deoxy-4-o-(3-deoxy-4-c-methyl-3-(methylamino)-.beta.-l-arabinopyranosyl)-6-o-(2,6-diamino-2,3,4,6-tetradeoxy-.alpha.-d-glycero-hex-4-enopyranosyl)-l-streptamine
o-3-deoxy-4-c-methyl-3-(methylamino)-.beta-l-arabinopyranosyl-(1->4)-o-(2,6-diamino-2,3,4,6-tetradeoxy-.alpha.-d-glycero-hex-4-enopyranosyl-(1->6))-2-deoxy-l-streptamine
sisomicin [mi]
sisomicin [who-dd]
URWAJWIAIPFPJE-YFMIWBNJSA-N
DB12604
Q3962119
(2r,3r,4r,5r)-2-(((1s,2s,3r,4s,6r)-4,6-diamino-3-(((2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-5-methyl-4-(methylamino)tetrahydro-2h-pyran-3,5-diol
sisomicin-sulfate
gtpl10858
HY-B1222A
CS-0013807

Research Excerpts

Overview

Sisomicin is a broad-spectrum aminoglycoside most closely related structurally to gentamicin C1a. It is a highly effective antibiotic for the treatment of UTI caused by gramnegative pathogens.

ExcerptReferenceRelevance
"Sisomicin is a naturally occurring aminoglycoside antibiotic produced by Micromonospora inyoensis, while dibekacin and netilmicin are both semisynthetic aminoglycosides. "( Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use.
Noone, P, 1984
)
3.15
"Sisomicin is a new broad-spectrum aminoglycoside most closely related structurally to gentamicin C1a. "( Sisomicin: a review of eight years' experience.
Sanders, CC; Sanders, WE,
)
3.02
"Sisomicin is a highly effective antibiotic for the treatment of UTI caused by gramnegative pathogens."( [Efficacy, tolerance, and pharmacokinetics of sisomicin in urinary tract infections (author's transl)].
Dobbelstein, H; Isbary, E; Lang, W, 1978
)
1.24
"Sisomicin is a new aminoglycoside aminocyclitol antibiotic with pharmacological similarities to gentamicin and tobramycin. "( Sisomicin in the treatment of severe or complicated urinary tract infections.
Bailey, RR; Peddie, B, 1978
)
3.14
"5-episisomicin (Sch 22591) is a novel semisynthetic aminoglycoside with a spectrum and potency similar to gentamicin in its activity against susceptible bacterial strains, but with increased potency against Pseudomonas, Providencia, and Proteus rettgeri. "( Chemotherapeutic evaluation of 5-episisomicin (Sch 22591), a new semisynthetic aminoglycoside.
Chiu, PJ; Miller, GH; Moss, E; Waitz, JA, 1978
)
1.05
"Sisomicin is an aminoglycoside effective against gramnegative germs. "( [Pharmacokinetic investigations on sisomicin in children (author's transl)].
Patsch, R; Richter, J; Sitka, U; Weingärtner, L, 1978
)
1.98
"Sisomicin is a new aminoglycoside, which sometimes is active against bacterial isolates resistant to other antibiotics of this group. "( [Experimental investigations concerning a topical application of sisomicin in the eye (author's transl)].
Krasemann, C; Mester, U; Stein, HJ, 1978
)
1.94
"Sisomicin proved to be an effective therapy in urinary tract infections and to a lesser extent in wound infections caused by gram-negative rods; favorable results have been observed in 91.6% and in 66.6% of the patients presenting these infections."( Sisomicin: Bacteriological and clinical evaluation.
Daneau, D; Gérad, M; Hensgens, C; Klastersky, J, 1975
)
2.42
"Sisomicin sulphate is a new-generation aminoglycoside with a broad spectrum of antimicrobial activity that includes Pseudomonas aeruginosa. "( Aqueous kinetics of sisomicin sulphate.
Bhatt, V; Desai, R; Desai, S; Sharma, R, 1992
)
2.05

Effects

ExcerptReferenceRelevance
"Sisomicin has been shown to interact synergistically with various beta-lactam antibiotics against enterococci, staphylocicci, Enterobacteriaceae, and nonfermentative gram-negative bacilli."( Sisomicin: a review of eight years' experience.
Sanders, CC; Sanders, WE,
)
2.3

Toxicity

ExcerptReferenceRelevance
"Animal experiments showed that all aminoglycosides cause similar toxic tubular and glomerular damage when investigated by qualitative morphology."( [Side effects of aminoglycosides: nephrotoxicity (author's transl)].
Beck, H; Freiesleben, H; Sack, K; Schulz, E; Züllich, B, 1976
)
0.26
" A significant side effect of aminoglycoside antibiotics is the production of hearing loss."( [Comparative ototoxicity of aminoglycoside antibiotics in a guinea pig model (author's transl)].
Brummett, RE, 1978
)
0.26
" Decreased tubular resorption of glucose and phosphate were observed with the most toxic regimens after extensive renal damage had occurred."( Comparative nephrotoxicity of aminoglycoside antibiotics in rats.
Bloch, R; Costello, R; Luft, FC; Maxwell, DR; Sloan, RS; Yum, MN, 1978
)
0.26
" The above correlation was used for calculation of the maximum value of the sisomycin safe concentration in blood serum."( [Pharmacokinetic analysis of the nephrotoxic effect of sisomycin].
Egorenko, GG; Eĭromdzhants, AA; Firsov, AA, 1981
)
0.26
" Safety was assessed from adverse event (AE) reporting, standard clinical laboratory procedures, and testing for renal, cochlear, and vestibular function."( Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects.
Borin, MT; Brooks, CD; Bruss, JB; Cass, RT; Havrilla, NA; Tack, KJ; Young, D, 2011
)
0.37
" Endotoxins were discussed as the cause for the adverse effects and sisomicin was identified as the lead impurity; batches containing sisomicin were contaminated with more impurities and were responsible for the fatalities."( Analysis of histamine and sisomicin in gentamicin: Search for the causative agents of adverse effects.
Holzgrabe, U; Wohlfart, J, 2021
)
1.16

Pharmacokinetics

Sisomicin (S ISO) was administered intramuscularly to 10 infants aged less than 1 year, 16 young children and 18 school children at doses of 1. A significant variability of the pharmacokinetic parameters of tobramycin and sisomicine was found.

ExcerptReferenceRelevance
" Biological half-life (90 minutes), urine recovery (60% in the fourth hour), renal clearance and skin blister levels at the end of infusion were almost identical for both antibiotics; total clearance was somewhat higher with sisomicin than with gentamicin."( Sisomicin: in vitro activity and pharmacokinetics.
Ahlendorf, W; Maleryzk, V; Simon, C, 1978
)
1.89
" The pharmacokinetic parameters of netilmicin were derived by analyzing the elimination data according to a two-compartment model."( Pharmacokinetic study of netilmicin.
Hirschman, SZ; Meyers, BR; Siegel, D; Wormser, G, 1977
)
0.26
" Pharmacokinetic parameters derived from the intramuscular and intravenous studies were quite similar."( Pharmacokinetic parameters of sisomicin.
Hirschman, SZ; Meyers, BR; Ribner, B; Yancovitz, S, 1976
)
0.54
" Linear relationships were defined between sisomicin serum half-life and the reciprocal of the endogenous creatinine clearance and serum creatinine concentration."( Clinical pharmacokinetics of sisomicin: dosage schedules in renal-impaired patients.
Dugal, R; Pechère, JC; Pechère, MM, 1976
)
0.81
" There were no pharmacokinetic differences of therapeutic significance between the three drugs."( [Pharmacokinetics and clinical observations of sisomicin, a newly developed aminoglycoside derivative (author's transl)].
Kemmerich, B; Koeppe, P; Langmaack, H; Lode, H, 1975
)
0.51
" There was good correlation between serum creatinine and sisomicin serum half-life values and a practical method is described for dose adjustment based on the relationship between serum half-lives and serum creatinine concentrations."( Treatment with sisomicin of complicated urinary tract infections in patients with varying degrees of renal function impairment, pharmacokinetics and dosage adjustment.
Madsen, P; Mosegaard, A; Tse, FL; Welling, PG, 1975
)
0.85
"Sisomicin (SMN) and cefotaxime (CTX) antimicrobial effect (AME) kinetics were studied under in vitro stimulation the drug monoexponential pharmacokinetic profiles mimicking normal and impaired elimination of SMN or CTX administered in various doses to humans."( In vitro simulated pharmacokinetics profiles: forecasting antibiotic optimal dosage.
Firsov, AA, 1991
)
1.72
"The general strategy in optimization of antibiotic dosage regimens included development of population or common regimens for an "average" patient (the 1st approximation), subpopulation regimens for patients of certain categories on the basis of interactions between the pharmacokinetic parameters and "patient factors" (the 2nd approximation) and individual regimens on the basis of the data of the pharmacokinetic monitoring (the 3rd approximation)."( [Pharmacokinetic monitoring of antibiotic therapy].
Firsov, AA, 1989
)
0.28
"The general principles of in-vitro simulation of drug pharmacokinetic profiles for linear one-, two- and multi-compartment models are described."( A dynamic model for in-vitro evaluation of antimicrobial action by simulation of the pharmacokinetic profiles of antibiotics.
Chernykh, VM; Firsov, AA; Fomina, IP; Kuznetsova, SM; Navashin, SM, 1989
)
0.28
"Relationships between concentration and antimicrobial effect (AME) of sisomicin (SMN) and cefotaxime (CTX) were established by simulating their pharmacokinetic profiles in an in vitro dynamic model."( [Correlation of dose-antimicrobial effect in modeling in vitro pharmacokinetic profiles of normal and impaired elimination of antibiotics].
Firsov, AA, 1989
)
0.51
" pneumoniae 5056 and the antibiotic concentration under conditions of sisomicin pharmacokinetic profiles reproduction after intramuscular administration within the levels of the therapeutic doses with an account of individual variability of the aminoglycoside concentration in the blood of humans."( [Principles for analyzing the kinetic curves of the antimicrobial effect in dynamic systems simulating the pharmacokinetic profiles of antibiotics].
Chernykh, VM; Firsov, AA; Fomina, IP, 1987
)
0.51
" Consequently, there were no significant changes in the levels of sisomicin in serum and the site of the nephrotoxic effect (cortical layer of the kidneys) and in the half-life of the aminoglycoside in the kidney cortical layer under the action of cefazolin."( [Interrelations in the changes in the pharmacokinetics and nephrotoxic effect of sisomycin as affected by cefazolin].
Danilova, VI; Egorenko, GG; Firsov, AA; Gagaeva, EV; Shtegel'man, LA, 1986
)
0.51
" For investigation of the kinetics of the antimicrobial effect of antibiotics at their varying levels, a universal dynamic system providing in vitro simulation of the pharmacokinetic profiles of the drugs in blood and tissues was developed."( [A dynamic system for the in vitro study of the kinetics of the antimicrobial effect of antibiotics in pharmacokinetic changes in their concentration].
Chernykh, VM; Firsov, AA; Kuznetsova, SM; Navashin, SM, 1985
)
0.27
" The decrease in the nephrotoxic effect was accompanied by a decrease in the sisomicin concentration in the blood serum and the site of the nephrotoxic effect (the kidney cortical layer) and the period of the aminoglycoside half-life in the kidney cortical layer under the action of cephalothin."( [Decrease of sisomicin nephrotoxicity as affected by cephalothin: pharmacokinetic evaluation].
Berezina, EK; Egorenko, GG; Firsov, AA; Gagaeva, EV; Shtegel'man, LA, 1985
)
0.87
" However, by the antibiotic blood levels it was possible to characterize in a complex the pharmacokinetic behaviour of the antibiotic in the perilymph by predicting the areas under the respective curves of the antibiotic concentration versus time."( [Sisomycin pharmacokinetics in the perilymph and blood serum--an approach to predicting its ototoxic effect].
Berezhinskaia, VV; Dolgova, GV; Eĭromdzhants, AA; Firsov, AA, 1985
)
0.27
" A significant variability of the pharmacokinetic parameters of tobramycin and sisomicin under conditions of the changing function of the kidney transplant was shown."( [Pharmacokinetic basis for using tobramycin and sisomicin in treating pyelonephritis of the transplanted kidney].
Belorusov, OS; Bogomolova, NS; Firsov, AA; Navashin, SM; Treskina, OS, 1983
)
0.75
" A pharmacokinetic study, performed in five patients, enables us to demonstrate the praticability of this method for the adaptation of the dosage regimen in renal insufficiency."( [Comparison of bacteriological and immunoenzyme methods for the serum determination of sisomicin. Pharmacokinetic application in the human].
Barre, J; Chousterman, M; Clausse, AM; Duval, J; Houin, G; Soussy, CJ; Tillement, JP, 1984
)
0.49
" It was shown that the data on the sisomicin renal excretion might be used for the purposes of the pharmacokinetic control."( [Pharmacokinetic prediction of the efficacy of using sisomicin in wound infections].
Blatun, LA; Danilova, VI; Firsov, AA; Navashin, PS, 1983
)
0.79
" The kidneys accumulated high amounts of dibekacin, and eliminated it with a half-life of about 7 days."( [Animal experiments on the nephrotoxicity, pharmacokinetics and therapeutic efficacy of dibekacin].
Bopp, S; Marre, R; Sack, K; Schulz, E, 1981
)
0.26
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Model-derived pharmacokinetic parameters and safety findings were generally consistent with previously reported plazomicin studies."( A Phase 1 Study of Intravenous Plazomicin in Healthy Adults to Assess Potential Effects on the QT/QTc Interval, Safety, and Pharmacokinetics.
Choi, T; Gall, J; Gibbons, JA; Riddle, V; Seroogy, J; Van Wart, S, 2019
)
0.51
" A previous population pharmacokinetic (PK) model was used to evaluate the dosage regimen in cUTI patients with different degrees of renal impairment."( Application of Population Pharmacokinetic Modeling, Exposure-Response Analysis, and Classification and Regression Tree Analysis to Support Dosage Regimen and Therapeutic Drug Monitoring of Plazomicin in Complicated Urinary Tract Infection Patients with Re
Iarikov, D; Jang, SH; Mishra, S; Reynolds, KS; Wu, K; Zhuang, L, 2022
)
0.72

Compound-Compound Interactions

The in vitro effects of Bay k 4999 in combination with gentamicin, tobramycin, amikacin sisomicin and netilmicin were compared against 20 different strains of Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and indole-positive-negative Proteus species.

ExcerptReferenceRelevance
"The in vitro effects of Bay k 4999 in combination with gentamicin, tobramycin, amikacin sisomicin and netilmicin in bacteriostatic (MIC) and bactericidal (MBC) concentrations were compared using the checkerboard dilution technique against 20 different strains of Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and indole-positive-negative Proteus species."( In vitro efficacy of Bay k 4999, a new ureido-penicillin, in combination with aminoglycosides against Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Proteus strains.
Daschner, FD; Langmaack, H; Steffens, A, 1979
)
0.48
"The in vitro activity of sisomicin and netilmicin alone and in combination with nafcillin, oxacillin and methicillin against 30 strains of enterococci was investigated."( In vitro activity of sisomicin and netilmicin alone and in combination with nafcillin, oxacillin and methicillin against enterococci.
Glotzbecker, C; Watanakunakorn, C, 1978
)
0.88
" Staphylococci isolated from the bones of therapeutic failures that had received rifampin alone or in combination with other antibiotics were highly resistant to rifampin (minimal inhibitory concentration, greater than 250 mug/ml), whereas the organisms recovered from animals not receiving rifampin remained sensitive."( Experimental osteomyelitis. IV. Therapeutic trials with rifampin alone and in combination with gentamicin, sisomicin, and cephalothin.
Norden, CW, 1975
)
0.47
" Evaluation of therapeutic efficacy of ureidopenicillins combined with sisomicin was performed on 90 rabbits, infected intravenously with heavy inocula."( In vitro and in vivo action of mezlocillin and azlocillin combined with sisomicin.
Dzierzanowska, D; Jeljaszewicz, J, 1983
)
0.73
"The efficacy of rifampin alone and in combination with sisomicin, cephalothin, sisomicin and cephalothin, or trimethoprim was measured in an experimental model of chronic osteomyelitis due to Staphylococcus aureus in rabbits."( Experimental chronic staphylococcal osteomyelitis in rabbits: treatment with rifampin alone and in combination with other antimicrobial agents.
Norden, CW,
)
0.38
"In vivo synergistic effects of cefodizime (CDZM) were investigated in combination with aminoglycosides (AGs), sisomicin (SISO) or dibekacin (DKB) against Pseudomonas aeruginosa in immunocompromised tumour bearing mice."( [Therapeutic efficacy of cefodizime in combination with aminoglycosides against systemic infections caused by Pseudomonas aeruginosa in immunocompromised tumour bearing mice].
Deguchi, K; Furukawa, T; Hyodo, A; Miyake, Y; Uji, T, 1993
)
0.5
" Synergy was observed when plazomicin was combined with meropenem, colistin or fosfomycin against both isolates, whilst the combination with tigecycline resulted in indifference."( In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
Culebras, E; Pena, I; Picazo, JJ; Rodríguez-Avial, C; Rodríguez-Avial, I, 2015
)
0.42
" To determine synergy with other antibiotics, plazomicin was combined with antibiotics in checkerboard assays against MDR Enterobacteriaceae, including isolates with resistance to aminoglycosides and β-lactams; 10 Escherichia coli isolates, 8 Klebsiella spp."( Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae.
Hall, D; Krause, KM; Marra, A; Pillar, C; Serio, AW; Shinabarger, D; Stoneburner, A; Thwaites, M, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
" We used the agar diffusion technique of microbial assay to determine the aqueous penetration and bioavailability of a subconjunctivally placed standard dose of 20 mg/0."( Aqueous kinetics of sisomicin sulphate.
Bhatt, V; Desai, R; Desai, S; Sharma, R, 1992
)
0.61
" The duration of the effective bioavailability of the drugs studied varied from 12 to 18 hours."( Ocular penetration of subconjunctivally injected gentamicin, sisomicin and cephaloridine.
Goyal, M; Jain, MR; Jain, V, 1988
)
0.52
" The mean absorption rate constants (ka) were 18."( [A pharmacokinetic investigation of sisomicin administered intramuscularly to children].
Iwai, N; Motohiro, T; Nishimura, T, 1984
)
0.54
" Intramuscular bioavailability of sisomicin for the doses of 25, 50, and 100 mg was greater than 95%."( Pharmacokinetic study of sisomicin in humans.
Chung, M; Schrogie, JJ; Symchowicz, S, 1981
)
0.85

Dosage Studied

Gentamicin, sisomicin and amikacin are useful against Serratia infections; but in each case, a higher dosage is needed. Sisomicine may be used for dosage adjustment in renal-impaired patients.

ExcerptRelevanceReference
" In the second group, the dosage of each antibiotic necessary to induce apnea is sought."( [Neuromuscular inhibition of new aminoglycoside antibiotics].
Baltar, I; Esplugues, J; Marti, JL; Orts, A, 1979
)
0.26
" This variation in penetration reflected individual differences in each dosage group and the increase in percent penetration that was observed during therapy."( Comparison of four aminoglycoside antibiotics in the therapy of experimental E. coli meningitis.
Mandaleris, CD; Sande, MA; Strausbaugh, LJ, 1977
)
0.26
" However, the appearance of granular casts was seen in 7 of 10 patients receiving the higher dosage of netilmicin (7."( Clinical and bacteriological evaluation of netilmicin in gram-negative infections.
Coppens-Kahan, L; Daneau, D; Klastersky, J; Meunier-Carpentier, F; Prevost, JM, 1977
)
0.26
" There were 10 animals in each dosage group."( [Comparative ototoxicity of aminoglycoside antibiotics in a guinea pig model (author's transl)].
Brummett, RE, 1978
)
0.26
" Dose-response data demonstrating linear recovery are included for all four aminoglycosides as well as a comparison of the GLC method with the microbiological method for the assay of gentamicin and amikacin."( Gas-liquid chromatographic method for the assay of aminoglycoside antibiotics in serum.
Gorbach, SL; Mayhew, JW, 1978
)
0.26
"3 mug/ml; 31 to 47% of the drug was excreted within the 8-h dosage interval."( Clinico-pharmacological studies of sisomicin in ill children.
Dugal, R; Hammerberg, S; Marks, MI; Vose, A, 1978
)
0.54
" Based on these results we recommend an individual, Sisomicin dosage for each age group."( [Pharmacokinetic investigations on sisomicin in children (author's transl)].
Patsch, R; Richter, J; Sitka, U; Weingärtner, L, 1978
)
0.79
"Netilmicin, gentamicin, tobramycin, amikacin, kanamycin, streptomycin, and sisomicin were given daily for 15 days to groups of rats at three dosage levels corresponding to 10, 15, or 25 times the dose recommended for humans on a weight basis."( Comparative nephrotoxicity of aminoglycoside antibiotics in rats.
Bloch, R; Costello, R; Luft, FC; Maxwell, DR; Sloan, RS; Yum, MN, 1978
)
0.49
" Depending on the dosage group, the mean urinary concentrations/24 h amounted to 46-51 mug/ml or 63 to 92 mug/ml, respectively."( [Sisomicin treatment of urinary tract infections (author's transl)].
Gillissen, J; Jost, M; Lobe, H; Weissbach, L, 1976
)
1.17
" In patients with impaired renal function the dosage interval should be increased according to the serum creatinine level, and in patients dependent on haemodialysis one standard dose at the end of each dialysis period should suffice."( Pharmacokinetics of sisomicin in patients with normal and impaired renal function; its efficacy in urinary tract infection.
Gruenwaldt, G; Lange, H; Naber, K; Roth, S; Scheer, M, 1976
)
0.58
" Gentamicin, sisomicin and amikacin are useful against Serratia infections; but in each case, a higher dosage is needed."( Comparative evaluation of five aminoglycosides for treatment.
Köhler, M; Naumann, P; Reintjens, E; Rosin, H, 1976
)
0.62
" Netilmicin levels in serum were above minimum inhibitory concentration values for most susceptible organisms for up to 8 h after dosing in normal individuals and for at least 12 h in uremic patients."( Netilmicin pharmacokinetics after single intravenous doses to elderly male patients.
Baumueller, A; Lau, CC; Madsen, PO; Welling, PG, 1977
)
0.26
" The latter relationship indicates that the half-life of sisomicin may be approximated as twice the serum creatinine concentration and may be used for dosage adjustment in renal-impaired patients."( Clinical pharmacokinetics of sisomicin: dosage schedules in renal-impaired patients.
Dugal, R; Pechère, JC; Pechère, MM, 1976
)
0.79
" The prophylactic effect upon ototoxicity of the administration of dimercaptopropanol or of dividing up the daily dosage was examined."( [Ototoxicity of the aminoglycoside antibiotics (author's transl)].
Federspil, P, 1976
)
0.26
"Indications, side effects, dosage and several pharmacokinetic properties of gentamicin, tobramycin, sisomicin, kanamycin, amikacin, and streptomycin are delt with in the first part."( [Aminoglycoside antibiotics from clinical viewpoint].
Lüthy, R, 1975
)
0.47
" There was little apparent toxicity with the dosage regimens used, although serum creatinine values were statistically but not clinically significantly increased in some patients following treatment."( Treatment with sisomicin of complicated urinary tract infections in patients with varying degrees of renal function impairment, pharmacokinetics and dosage adjustment.
Madsen, P; Mosegaard, A; Tse, FL; Welling, PG, 1975
)
0.61
" They are the following: consideration of the structure of the antibiotic use, improvement of infection diagnosis, the use of computers in epidemiological supervision of antibiotic resistance, the use of "old" antibiotics in new dosage forms, pharmacokinetic monitoring."( [Ways of increasing the effectiveness of antibacterial therapy in newborns].
Strachunskiĭ, LS, 1991
)
0.28
"The general strategy in optimization of antibiotic dosage regimens included development of population or common regimens for an "average" patient (the 1st approximation), subpopulation regimens for patients of certain categories on the basis of interactions between the pharmacokinetic parameters and "patient factors" (the 2nd approximation) and individual regimens on the basis of the data of the pharmacokinetic monitoring (the 3rd approximation)."( [Pharmacokinetic monitoring of antibiotic therapy].
Firsov, AA, 1989
)
0.28
"Potentiality of designing individual dosage of sisomicin and gentamicin in regard to "patient factors" was estimated."( [Individual schedule of administration of aminoglycosides with reference to anatomo-physiological and pathological factors].
Alekseeva, ME; Firsov, AA; Kashina, LB; Lukomskiĭ, GI; Manuĭlov, KK, 1989
)
0.53
" The procedure may be used for routine sanitary inspection of ambient air for every of the above antibiotics in the absence of the other in production of the substances and their dosage forms."( [Spectrophotometric determination of amikacin and sisomicin in the air using the Hantzsch reaction].
Churagulova, NK, 1987
)
0.53
" The regularities revealed under such conditions do not usually reflect the peculiar effect of the drugs in vivo, since with the use of the routine schemes of dosing the drug levels in the body fluids always vary."( [A dynamic system for the in vitro study of the kinetics of the antimicrobial effect of antibiotics in pharmacokinetic changes in their concentration].
Chernykh, VM; Firsov, AA; Kuznetsova, SM; Navashin, SM, 1985
)
0.27
" Evaluation of Td may be useful in predicting the optimal dosing intervals."( [Kinetics of the antimicrobial effect in a dynamic system: the microcalorimetric recording method and choice of parameters for characterizing kinetic curves].
Chernykh, VM; Firsov, AA, 1985
)
0.27
"The therapeutic efficacy, tolerance and pharmacokinetics of sisomicin, gentamicin and a new dosage form of kanamycin sulfate as an ampoule solution for intravenous injection were studied clinically."( [Present-day aminoglycosides in the treatment of suppurative-septic diseases].
Firson, AA; Kolker, II; Lobuseva, AN; Navashin, PS; Pozdniakova, VP, 1985
)
0.51
" For many cases, SISO was given at a daily dosage of 100 mg, and a single dose was infused over about 1 hour."( [Clinical evaluation of sisomicin following intravenous drip infusion in respiratory tract infections].
Isobe, H; Ito, R; Nagahama, F; Ohashi, R; Osaki, Y; Sasaki, N; Sasaki, Y; Shimomura, J; Tamura, T; Yozawa, K, 1985
)
0.58
" This result suggested that dosage regimen should be adjusted in patients with renal impaired function."( [Clinical evaluation of sisomicin in the treatment of complicated chronic urinary tract infections administered by intravenous infusion].
Suzuki, K; Tamai, H, 1985
)
0.58
" On the basis of this correlation a nomogram providing a decrease in the percentage of the errors in determining the dosage intervals was plotted."( [Pharmacokinetic basis for using tobramycin and sisomicin in treating pyelonephritis of the transplanted kidney].
Belorusov, OS; Bogomolova, NS; Firsov, AA; Navashin, SM; Treskina, OS, 1983
)
0.52
" A pharmacokinetic study, performed in five patients, enables us to demonstrate the praticability of this method for the adaptation of the dosage regimen in renal insufficiency."( [Comparison of bacteriological and immunoenzyme methods for the serum determination of sisomicin. Pharmacokinetic application in the human].
Barre, J; Chousterman, M; Clausse, AM; Duval, J; Houin, G; Soussy, CJ; Tillement, JP, 1984
)
0.49
"53 microgram/ml for sisomicin at 90 minutes after dosing administration."( [Pharmacokinetics of cefotetan and an aminoglycoside preparation in combined administration. 1. Individual quantification of cefotetan and sisomicin by bioassay and their absorption, distribution, and excretion in rats when given together].
Ikeda, C; Tachibana, A; Yano, K, 1982
)
0.79
" After repetitive dosing a distinct tendency to accumulation (highest renal concentration: 330 microgram/g) could be detected."( [Animal experiments on the nephrotoxicity, pharmacokinetics and therapeutic efficacy of dibekacin].
Bopp, S; Marre, R; Sack, K; Schulz, E, 1981
)
0.26
" Since the drugs were administered at different dosages, a blinded investigator was employed to assess treatment response, while an unblinded investigator was responsible for making dosage adjustments based on each patient's renal function and clinical response."( Comparative clinical trial of sisomicin and gentamicin in serious systemic gram-negative infections.
Danzig, M; Lorber, R; Malfitan, VA, 1981
)
0.55
" The purpose was not to expose patients to potentially toxic high peak concentrations of drug while maintaining these concentrations during the current therapeutic dosing intervals of 8 to 12 hr."( Pharmacokinetic study of sisomicin in humans.
Chung, M; Schrogie, JJ; Symchowicz, S, 1981
)
0.57
" The 15-mg/kg dose did not accumulate with repeated dosing over 5 days."( Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects.
Borin, MT; Brooks, CD; Bruss, JB; Cass, RT; Havrilla, NA; Tack, KJ; Young, D, 2011
)
0.37
" Due to limited efficacy and safety data, plazomicin is indicated for the treatment of cUTIs in adults with limited or no alternative treatment options, using a dosage regimen of 15 mg/kg intravenously every 24 hours for 4-7 days."( Plazomicin: A Next-Generation Aminoglycoside.
Chahine, EB; Cho, JC; Piccicacco, N; Shaeer, KM; Zmarlicka, MT, 2019
)
0.51
" A lack of pediatric-specific comparative effectiveness data, uncertain pediatric dosing regimens for several agents, and a relative lack of new antibiotics with pediatric indications approved by the US Food and Drug Administration (FDA) collectively present unique challenges for children."( Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.
Chiotos, K; Gerber, JS; Hayes, M; Tamma, PD, 2020
)
0.56
" The objective of this article is to provide the scientific rationales behind the recommended dosage regimen and therapeutic drug monitoring (TDM) of plazomicin in cUTI patients with renal impairment."( Application of Population Pharmacokinetic Modeling, Exposure-Response Analysis, and Classification and Regression Tree Analysis to Support Dosage Regimen and Therapeutic Drug Monitoring of Plazomicin in Complicated Urinary Tract Infection Patients with Re
Iarikov, D; Jang, SH; Mishra, S; Reynolds, KS; Wu, K; Zhuang, L, 2022
)
0.72
" Yet, selecting an appropriate dose and appropriate time to administer the dose with dosing frequency requires extensive understanding of the interplay between drug pharmacokinetics/pharmacodynamics (PK/PD), the host immune system, and bacterial-resistant mechanisms."( Use of pharmacokinetic/pharmacodynamic approaches for dose optimization: a case study of plazomicin.
Luterbach, CL; Rao, GG, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
amino cyclitol glycoside
aminoglycoside antibiotic
beta-L-arabinoside
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (126)

Assay IDTitleYearJournalArticle
AID560598Antimicrobial activity against Escherichia coli JM109 transformant harboring pSTV28 plasmid by microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID523066Antibacterial activity against Escherichia coli JM83 harboring empty pHF022 vector by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID1137204Antimicrobial activity against Bacillus subtilis ATCC 6633 by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID1137193Antimicrobial activity against Pseudomonas aeruginosa St. M. 1395 by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1137201Antimicrobial activity against Providencia rettgeri Anderson by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID522928Antibacterial activity against Escherichia coli JM83 producing aminoglycoside 2''-2a phosphotransferase by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID583215Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing armA methylase by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1271377Antimicrobial activity against Gram-positive Bacillus cereus ATCC 17788 after 16 to 24 hrs by micro-dilution method2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID583212Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing ANT(3)-2 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID278806Antimicrobial activity against Stenotrophomonas maltophilia K279a (aph FS) mutant2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID583214Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing ANT(3)-4a by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID1137215Antiprotozoal activity against Entamoeba histolytica JH1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1137206Antimicrobial activity against Staphylococcus aureus Wood by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID65065Percent killing of the total Escherichia coli K12 (ATCC 25868) cells at the C50 concentration was determined.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID1137196Antimicrobial activity against Klebsiella pneumoniae Adler 17 carrying APH(3')-I by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID1271379Antimicrobial activity against Gram-positive Listeria monocytogenes ATCC 19115 after 16 to 24 hrs by micro-dilution method2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID522933Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a D268N mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID1137200Antimicrobial activity against Providencia rettgeri Membel by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID583211Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing ANT(2'')-1 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID583216Antibacterial activity against aminoglycoside-resistant Providencia stuartii expressing ANT(2')-1 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID1137208Antimicrobial activity against Staphylococcus aureus 59N by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID65071Estimated rate of [3H]DHS uptake in Escherichia coli K12 (ATCC 25868)1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID583227Antibacterial activity against wild type Pseudomonas aeruginosa expressing efflux pump by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID1137213Acute toxicity in albino CF1 mouse1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID583221Antibacterial activity against aminoglycoside-resistant Staphylococcus aureus expressing APH(2'') + AAC(6') by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID522930Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a phosphotransferase R92H/D268N mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID1271383Antimicrobial activity against Gram-negative Haemophilus influenzae ATCC 51907 after 16 to 24 hrs by micro-dilution method2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID583231Antibacterial activity against Pseudomonas aeruginosa expressing AAC(3)-1 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID583230Antibacterial activity against Pseudomonas aeruginosa expressing ANT(4')-2 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID1271376Antimicrobial activity against Gram-positive Bacillus anthracis str. Sterne after 16 to 24 hrs by micro-dilution method2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID1137205Antimicrobial activity against Staphylococcus aureus 209 P by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID583219Antibacterial activity against aminoglycoside-resistant Staphylococcus aureus expressing ANT(4')-1 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID583224Antibacterial activity against Acinetobacter baumannii ATCC 19606 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID428873Antibacterial activity against Escherichia coli JM109 carrying pMCL210 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID583209Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing ANT(6')-1 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID207728Inhibitory activity against the displacement of Picogreen from fMet-tRNA(fMet) by the aminoglycoside2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Inhibition of bacterial IF2 binding to fMet-tRNA((fMet)) by aminoglycosides.
AID207731Maximal inhibition of the aminoglycoside on Staphylococcus aureus IF-2 binding to fMet-tRNA(fMet)2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Inhibition of bacterial IF2 binding to fMet-tRNA((fMet)) by aminoglycosides.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID560600Antimicrobial activity against Escherichia coli JM109 transformant harboring pSTV28 plasmid expressing aac(6')-Iaf (TTG-ATG) mutant gene by microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID278805Antimicrobial activity against Stenotrophomonas maltophilia K279a mutant2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID560599Antimicrobial activity against Escherichia coli JM109 transformant harboring pSTV28 plasmid expressing aac(6')-Iaf wild type gene by microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID1271385Antimicrobial activity against Mycobacterium smegmatis MC2-155 after 16 to 24 hrs by micro-dilution method2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID522932Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a N196D mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID583222Antibacterial activity against aminoglycoside-resistant Acinetobacter spp. expressing APH(3')-6 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1137195Antimicrobial activity against Pseudomonas aeruginosa GN 315 carrying AAC(6') by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID1271381Antimicrobial activity against Gram-positive methicillin-resistant Staphylococcus aureus 1 after 16 to 24 hrs by micro-dilution method2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID583217Antibacterial activity against aminoglycoside-resistant Serratia marcescens expressing ANT(2''), AAC(6') by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID1271384Antimicrobial activity against Gram-negative Pseudomonas aeruginosa PAO1 after 16 to 24 hrs by micro-dilution method2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID583213Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing ANT(3')-1b by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1137214Antiprotozoal activity against Trichomonas vaginalis after 48 hrs1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1271378Antimicrobial activity against Gram-positive Bacillus subtilis 168 after 16 to 24 hrs by micro-dilution method2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID583225Antibacterial activity against aminoglycoside-resistant Acinetobacter calcoaceticus expressing AAC(6')-1 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID1137209Antimicrobial activity against Streptococcus pyogenes C by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID583229Antibacterial activity against Pseudomonas aeruginosa expressing mexXY operon by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID1137202Antimicrobial activity against Serratia marcescens Dalton by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID428872Antibacterial activity against Escherichia coli JM109 carrying pMCL-BE by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID1137194Antimicrobial activity against Pseudomonas aeruginosa Stone 130 carrying AAC(3) by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID560590Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ798 by microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID1137207Antimicrobial activity against Staphylococcus aureus Ziegler by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID405822Antimicrobial activity against Escherichia coli DH5alpha2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID1137192Antimicrobial activity against Pseudomonas aeruginosa St. M. 762 by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID207727Denaturation rate constant of IF2 in the presence of aminoglycoside2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Inhibition of bacterial IF2 binding to fMet-tRNA((fMet)) by aminoglycosides.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID278803Antimicrobial activity against recombinant Escherichia coli DHalpha expressing pBAD [aph(3')-2]2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID1137197Antimicrobial activity against Klebsiella pneumoniae Georgetown 3694 carrying APH(2'') by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID428871Antibacterial activity against Escherichia coli CSH-2 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID207729Inhibitory activity of the aminoglycoside on Staphylococcus aureus IF-2 binding to fMet-tRNA (fMet)2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Inhibition of bacterial IF2 binding to fMet-tRNA((fMet)) by aminoglycosides.
AID1137187Antimicrobial activity against Escherichia coli ATCC 10536 by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID1137212Antimicrobial activity against Streptococcus pyogenes Alvarez by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID1137190Antimicrobial activity against Escherichia coli JR88 carrying AAC(3) by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID278801Antimicrobial activity against recombinant Escherichia coli DH5alpha expressing pBAD2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID207730Maximal inhibition against the displacement of Picogreen from fMet-tRNA(fMet) by the aminoglycoside2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Inhibition of bacterial IF2 binding to fMet-tRNA((fMet)) by aminoglycosides.
AID1137198Antimicrobial activity against Providencia 164 carrying AAC(2')-I by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID1137216Antiprotozoal activity against Histomonas meleagridis1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID522929Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a phosphotransferase N196D/D268N mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID583210Antibacterial activity against Escherichia coli ATCC 25922 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID278802Antimicrobial activity against recombinant Escherichia coli DH5-alpha expressing pBAD in the presence of arabinose2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID560591Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ799 by microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID1137199Antimicrobial activity against Proteus mirabilis Harding by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID1271382Antimicrobial activity against Gram-positive methicillin-resistant Staphylococcus aureus 2 after 16 to 24 hrs by micro-dilution method2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID583218Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID405816Antimicrobial activity against Escherichia coli DH5alpha harboring recombinant pIMPAR312007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID428870Antibacterial activity against Escherichia coli CSH-2 carrying Escherichia coli ARS3 pARS3 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID1137210Antimicrobial activity against Streptococcus pyogenes 27 by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID1137189Antimicrobial activity against Escherichia coli LA290R55 carrying ANT(2'') by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID583220Antibacterial activity against aminoglycoside-resistant Staphylococcus aureus expressing APH(3')-3 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID199517Compound was tested for the inhibition of Rev-RBE RNA complex formation1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Modeling RNA-ligand interactions: the Rev-binding element RNA-aminoglycoside complex.
AID583232Antibacterial activity against Pseudomonas aeruginosa expressing AAC(6')-2 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID583226Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID1271380Antimicrobial activity against Gram-positive Staphylococcus aureus ATCC 29213 after 16 to 24 hrs by micro-dilution method2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID1137211Antimicrobial activity against Streptococcus pyogenes Group A Cruz by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID1137203Antimicrobial activity against Salmonella typhimurium Gr. B. by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID1137191Antimicrobial activity against Escherichia coli HL97/W677 carrying AAC(6') by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID428869Antibacterial activity against Escherichia coli isolate ARS3 carrying pARS3 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID583208Antibacterial activity against Klebsiella pneumoniae ATCC 10031 by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID583228Antibacterial activity against efflux pump deficient Pseudomonas aeruginosa by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID278804Antimicrobial activity against recombinant Escherichia coli DH5-alpha expressing pBAD [aph(3')-2] in the presence of arabinose2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
AID583223Antibacterial activity against aminoglycoside-susceptible Acinetobacter baumannii by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Synthesis and spectrum of the neoglycoside ACHN-490.
AID65062Lethal dose required to kill 90% of the Escherichia coli K12 (ATCC 25868) cell population1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID522931Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a phosphotransferase R92H mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID65059Concentration required for half maximum rate of enhanced [3H]DHS uptake in Escherichia coli K121987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID1137188Antimicrobial activity against Escherichia coli Baker 2 carrying APH(3')-I by tube dilution method1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (548)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990398 (72.63)18.7374
1990's32 (5.84)18.2507
2000's21 (3.83)29.6817
2010's62 (11.31)24.3611
2020's35 (6.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.49 (24.57)
Research Supply Index6.45 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index67.15 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials42 (7.09%)5.53%
Reviews33 (5.57%)6.00%
Case Studies12 (2.03%)4.05%
Observational0 (0.00%)0.25%
Other505 (85.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas [NCT00202891]Phase 40 participants (Actual)Interventional2007-05-31Withdrawn(stopped due to No further local interest in pursuing the study.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]